Skip to content
DataLookout
Menu

NCT07937852

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS)

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Number of Participants With Adverse Events (AEs)
Timeframe: Up to approximately 2 years

Secondary (16)

Change in Expanded Disability Status Scale (EDSS) Score Over Time
Change in 9-hole Peg Test (9-HPT) Over Time
Change in Timed 25-foot Walk Test (T25FWT) Over Time
Time to Onset of Composite 24-week Confirmed Disability Progression (cCDP24)
Time to Onset of 24-week Confirmed Disability Progression (CDP24)
Show 11 moreShow less
Time to Onset of Modified cCDP24
Time to Onset of 24-week Confirmed Disability Improvement (CDI24)
Number of New or Enlarging T2 Magnetic Resonance Imaging (MRI) Lesions
Number of T1 Hypointense MRI Lesions
Change in Total Volume of T2 Lesions
Change in Total Volume of T1 Hypointense Lesions
Change in Total Brain Volume
Annualized Relapse Rate (ARR) (for Relapsing Multiple Sclerosis [RMS] Participants Only)
Change in Patient-reported Outcome Measure Information System/Quality of Life in Neurological Disorders - Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a) Over Time
Change in Multiple Sclerosis Impact Scale - 29-item (MSIS-29), Version 2 Physical Scale Over Time
Change in MSIS-29 Psychological Scale Over Time

Arms and interventions

FenebrutinibExperimental

Participants receiving fenebrutinib in OLE of their parent study may be eligible for enrollment in this extension study. Participants will continue fenebrutinib treatment at the dosage and route of administration received at the time of rollover from the parent study.

Drugs: Fenebrutinib